Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.

Trial Details

NCT ID

NCT05528458

Phase

PHASE2

Sponsor

Samsung Medical Center

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

Osimertinib 80Mg Tab

Locations (sample)

Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

Provision of informed consent prior to any study specific procedures
Adult male or female patients, aged from 30 to 75 years
Pathologic proven lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with wel…
The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →